Itziar Erkizia Jauregi
Senior research technician
Host genetic and immune factors drive evasion of HIV-1 pathogenesis in viremic non-progressors.
Preclinical development of humanized monoclonal antibodies against CD169 as a broad antiviral therapeutic strategy.
Impact of obefazimod on viral persistence, inflammation, and immune activation in people with HIV on suppressive antiretroviral therapy.
Author Correction to: SARS-CoV-2 interaction with Siglec-1 mediates trans-infection by dendritic cells.
A non-infectious cell-based phenotypic assay for the assessment of HIV-1 susceptibility to protease inhibitors.